Although previous data have shown that ambrisentan prevents peritoneal metastasis in SOC xenografts [30], our study is the first to demonstrate that bosentan is effective in controlling tumor dissemination by targeting the metastatic potential of heterotypic spheroids, associated with enhanced apoptosis in cancer cells, fibroblasts and endothelial cells expressing ETBR, placing them as the cornerstone of peritoneal metastasis. Here, EDNRB is linked to cancer.